CompletedNCT00212836

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)

Researchers compared asenapine and olanzapine, tracking side effects to assess safety in people with schizophrenia.

Medication studyAges 18+

The study in practice

Understand this study

Researchers compared asenapine and olanzapine, tracking side effects to assess safety in people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Study clarity

Study start dateStarted: April 21, 2005

Recruitment status: Completed
Enrollment listed in the registry: 481
Sponsor: Organon and Co
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: Over 18 Years
Official registry ID: NCT00212836
Official title: Show the full official title
A Multicenter, Double-Blind, Flexible -Dose, 6-Month Trial Comparing the Efficacy Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia

Completed

Locations not listed

FAQ

What did researchers investigate?

Researchers compared asenapine and olanzapine, tracking side effects to assess safety in people with schizophrenia.

Who is behind this study?

The study sponsor is Organon and Co.

Did this study involve medication?

Yes. The study involved medication, including asenapine and olanzapine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.